Vision Changes on Semaglutide: What to Know

Three different things get bundled together under this question, and they carry very different levels of urgency. Separating them is most of the work.

The one that is an emergency

Sudden loss of vision, or eyesight that is rapidly getting worse, means contact a doctor without delay. Same day, not at your next appointment.

That advice comes from European regulators, and it is the practical takeaway from everything below. It applies whether the vision loss is in one eye or both, whether or not there is pain, and whether or not you think it could be something else.

What the NAION question is about

NAION stands for non-arteritic anterior ischemic optic neuropathy: damage to the optic nerve from reduced blood flow. It usually causes sudden, painless vision loss in one eye and is generally not reversible.

In June 2025 the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide medicines, and recommended adding it to the product information with a frequency of very rare, meaning it may affect up to 1 in 10,000 people taking it. Their guidance is that if NAION is confirmed, semaglutide should be stopped.

As of September 2026, the US prescribing information for Wegovy and Ozempic does not carry a NAION or optic neuropathy warning. UK and Australian regulators have since aligned with the European position, so the US is currently the outlier among them.

Be careful how you read that. A warning that is absent from one country’s label is a fact about regulatory timing, not evidence that the risk is not real. It means a US patient reading their own label will not find this and a European one will, which is a reason to know it rather than a reason to dismiss it.

Holding the numbers correctly

This is where it is easy to frighten yourself unnecessarily, so it is worth being careful.

A study published in JAMA Ophthalmology in 2024 found a substantially higher hazard of NAION among patients prescribed semaglutide compared with matched patients on other medications, with hazard ratios of about four in people with type 2 diabetes and about eight in people treated for overweight or obesity.

Those sound alarming, and two things keep them in proportion.

They are relative, not absolute. A large multiple of a very small number is still a small number. The European regulator’s frequency category, up to 1 in 10,000, is the absolute figure, and that is the one that describes your odds.

The study population was not the general population. It looked back at people seen by neuro-ophthalmologists at one academic center, meaning everyone in it had already been referred for an eye problem. That design is good at detecting a signal and poor at telling you the rate in ordinary patients, and the groups were small with very wide confidence intervals.

Larger studies since have disagreed with each other. Some population-based analyses have found an increased risk and at least one large one has not. The picture is genuinely unsettled, which is roughly what a very rare event looks like while it is being studied.

So the honest summary: there is a real signal, regulators in Europe took it seriously enough to act, the absolute risk remains very low, and the sensible response is knowing the warning sign rather than changing your plans.

Consider this scenario: someone reads a headline about a sevenfold increase and spends a week deciding whether to stop a medication that is working. What would actually protect them takes thirty seconds to learn: if vision suddenly goes, get seen immediately. Nothing else needed to change, and stopping alone would have carried its own consequences.

A different eye issue, and this one is on the US label

Diabetic retinopathy complications are a separate matter and they are in the US prescribing information.

The label’s point is counterintuitive: rapid improvement in blood glucose control has been associated with temporary worsening of diabetic retinopathy. The driver is the speed of the improvement, not the medication harming eyes.

If you have type 2 diabetes and any retinopathy, raise this with whoever manages your eyes before or soon after starting. It usually means monitoring rather than not treating. If you do not have diabetes, it does not apply to you.

The common, much less serious one

Blurry vision that comes and goes, particularly in the early weeks, is frequently about blood sugar and fluid shifts rather than anything structural. The lens responds to changing glucose levels, and vision can be genuinely unstable while things are moving. It usually settles.

Two practical notes: do not get new glasses prescribed during a period of rapid change, and mention it at a routine contact rather than as an emergency. And if blurring comes with dizziness on standing and reduced urination, the problem is probably dehydration rather than your eyes.

What to do about all of this

Get seen urgently for: sudden vision loss in one or both eyes, vision that is rapidly deteriorating, a dark or missing area in your field of view, or vision loss with eye pain or headache.

Raise at a routine contact: blurry vision that comes and goes, changes over weeks rather than hours, or anything that concerns you and is not in the urgent list.

Before starting, tell your prescriber if you have diabetic retinopathy, any existing optic nerve condition, or a previous episode of sudden vision loss. Our guide on how tirzepatide and semaglutide side effects compare covers the broader differences between the products, and the NAION signal specifically concerns semaglutide rather than the class as a whole.

Keep your routine eye appointments, and if you have diabetes keep the screening schedule you were given rather than relying on noticing something.

Do not stop your medication on your own because of a vision change. Get assessed first, because what should happen next depends on the cause.

Keeping perspective

Most people on these medications have no eye problems at all, and the commonest visual complaint is temporary blurring that resolves.

The reason to read any of this is not to worry. It is so that if something sudden happens, you recognize it as urgent instead of waiting to see whether it improves.

If a dose increase is coming up and you have had visual symptoms, mention it beforehand. Our guide on when to increase your tirzepatide dose covers that timing, and our guide on getting the most out of your GLP-1 treatment covers what monitoring should look like.

The short version

Sudden or rapidly worsening vision loss is a same-day emergency, and that is the one thing to take away. European regulators added NAION to semaglutide labelling in 2025 as a very rare side effect, up to 1 in 10,000, while US labelling does not currently mention it. The alarming hazard ratios you may have seen are relative figures from a referral eye clinic, not your odds, and larger studies since have not all agreed. Diabetic retinopathy is a separate issue, is on the US label, and is about how fast glucose improves. And ordinary blurring in the early weeks is usually blood sugar settling, so do not buy new glasses in the middle of it.

If you want a provider who will ask about symptoms like these rather than wait for you to raise them, TrimRx includes ongoing provider access alongside treatment.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.